Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy

Inclusion Criteria:

• Patients must have histologically I-III epithelial carcinoma of the ovary, fallopiantube or peritoneum or Stage IVA disease in which is there complete resolution ofdisease (pleural effusion) with chemotherapy

• Patients must have undergone cytoreductive surgery and 3-8 cycles of platinum-basedsystemic chemotherapy prior to the second look surgery. Systemic platinum basedchemotherapy must be completed less than 18 weeks prior to second look surgery.

• Cytoreductive surgery must result in an R-0, R-1 resection prior to systemicchemotherapy

• The intraoperative peritoneal adhesion index should be < 10.

• Patients must be without clinical evidence of disease including a negative exam,imaging (CT or PET/CT) and normal tumor markers (CA125) after completion of systemicchemotherapy.

• Age ≥ 18 years.

• ECOG performance status ≤ 2.

• Patients must have adequate organ and marrow function as defined below (within 30days of registration): absolute neutrophil count >1,500/mcL; platelets >100,000/mcL;total bilirubin ≤ 1.5 mg/dL; creatinine clearance ≥ 50 mg/dL; AST(SGOT)/ALT(SGPT) ≤ 3X; institutional upper limit of normal; alkaline phosphatase 3X institutional upperlimit of normal

• Adequate contraception and negative pregnancy test if pregnancy possible.

• Ability to understand and the willingness to sign an IRB-approved informed consentdocument.

Exclusion Criteria:

• Patients greater than 18 weeks from their last course of systemic platinum basedchemotherapy

• Patients who have received additional chemotherapy for the ovarian cancer afterprimary therapy as outlined above.

• Patients may not have received prior abdominal or pelvic radiation.

• Extensive intra-abdominal adhesive disease noted at the time of initialcytoreductive surgery with PAI of >10 as defined above

• Intra-abdominal infection associated with initial cytoreductive surgery requiringextended hospitalization or related to systemic chemotherapy requiringhospitalization for therapy

• History of allergic reactions attributed to compounds of similar chemical orbiologic composition to carboplatin.

• Uncontrolled intercurrent illness including, but not limited to ongoing or activeinfection, symptomatic congestive heart failure, unstable angina pectoris, cardiacarrhythmia, or psychiatric illness/social situations that would limit compliancewith study requirements.

• Pregnancy

Men are excluded from participation due to the site-specific nature of the disease being studied.